Bruno Sobral executive and scientific director of the Virginia BioInformatics Institute at Virginia Tech and also its founding director is stepping down effective March 2.
Sobral will remain on staff to continue his scientific work in cyberinfrastructure and pathosystems biology. He is professor of plant pathology at the university.
Sobral was appointed director in 2000. He is director of the PathoSystems Biology Group and the Cyberinfrastructure Group at Virginia Tech. He also holds appointments as professor, Department of Plant Pathology, Physiology and Weed Science in the College of Agriculture and Life Sciences and adjunct professor of Cancer Biology, Comprehensive Cancer Center, at Wake Forest University.
Michael Gilman, has been named to the Board of Directors of Gene Network Sciences Gilman is founder and Chief Executive Officer of Stromedix and former Executive Vice President of Research at Biogen Idec.
Gilman has been Chief Executive Officer of Stromedix since June 2006. He was previously Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000.
Prior to that post, he held several positions at ARIAD Pharmaceuticals including Executive Vice President and Chief Scientific Officer and was on the scientific staff of Cold Spring Harbor Laboratory where his research focused on mechanisms of signal transduction and gene regulation.
He holds a PhD in biochemistry from University of California, Berkeley and an S.B. in Life Sciences from Massachusetts Institute of Techology.
IO Informatics announced the addition of new members to its Working Group on Informatics for Personalized Medicine.
The new members are Kathy Gibson from Helio Consulting Uwe Christians from the University of Colorado and Eurofins Medinet Denver, Herbert Fritsche from MD Anderson Cancer Center , and Dan Crowther from Wyeth.
Christians is the Director of the Clinical Nutrition Research Unit Mass Spectrometry Core at the University of Colorado, a professor in the Department of Anesthesiology, and a professor in the Department of Pharmacology, Medizinische Hochschule Hannover in Germany. His main research interests are the development of translational strategies and novel concepts for drug development, pharmaco- and toxicodynamic therapeutic drug monitoring and personalized medicine.
He received his M.D. and his Ph.D. in Experimental and Clinical Pharmacology and Toxicology from the Medizinische Hochschule Hannover in Hannover, Germany, where he is a board-certified pharmacologist, toxicologist, and clinical pharmacologist.
Crowther is head of Informatics for the Translational Medicine Research Collaboration, which involves four Scottish universities, four NHS trusts, Scottish Enterprise, and Wyeth and which seeks to develop a network of clinical and scientific researchers to discover and develop biomarkers.
Crowther received his degree in biochemistry and his PhD in molecular biology from Oxford University. Prior to joining Wyeth, he worked at GlaxoSmithKline and its legacy companies for 9 years where he managed a team of computational biologists within thebioinformatics division.
Fritsche is Professor and Chief of the Clinical Chemistry Laboratory in the Department of Laboratory Medicine at the University of Texas M. D. Anderson Cancer Center. In addition, he conducts an active research program in the development and validation of cancer diagnostics. Currently, he is a member of the editorial board of six scientific journals, a Fellow in the National Academy of Clinical Biochemistry, a member of the Tumor Marker Expert Panel of the American Society of Clinical Oncology, the Tumor Marker Guidelines Committee for NACB, the Technology Expert Panel for Blue Cross Blue Shield, and is an active member of three professional societies.
Gibson is president and founder of Helio Consulting, a management and technology consulting company. Prior to forming Helio, Kathy spent thirteen years with Pfizer, as Vice President of Corporate Business Development and Innovation and also as Vice President and CIO for Worldwide Research Informatics.
Richard Resnick is the new Vice President, Software and Professional Services at GenomeQuest.
Resnick will lead GenomeQuest’s software development team and for managing the delivery of professional services to GenomeQuest’s customers.
Prior to joining GenomeQuest, Resnick was the CEO of Harmony Line, an MIT Media Lab startup and the commercial force behind the Media Lab’s music composition software, Hyperscore. Prior to Harmony Line, Resnick spent over a decade in the sequence informatics industry, founding and selling Mosaic Bioinformatics in 1999 to NetGenics, working as the global bioinformatics software manager for Wyeth, and contributing to the Human Genome Project under Eric Lander at the MIT Whitehead Institute for Biomedical Research.
Mr. Resnick holds an M.B.A. from the MIT Sloan School of Management, an M.S. in Computer Science from Worcester Polytechnic Institute, and a B.S. in Computer Science from the University of Massachusetts at Amherst.